吉西他滨联合顺铂方案二线治疗晚期卵巢癌的临床研究

目的 对紫杉类和卡铂药物一线化疗后复发的晚期卵巢癌患者进行吉西他滨联合顺铂方案化疗,评估其疗效及毒性.方法 紫杉类和卡铂一线化疗后复发的晚期卵巢癌患者接受吉西他滨1.0 g/m2,i.v.,dl,d8;顺铂25mg/m2,i.v.,d1～d3; 21天为1个疗程,至少应用2个疗程,然后评价临床疗效和毒性,并进行随访.结果 30例患者治疗总缓解率53.3％.其中完全缓解3例,部分缓解13例,无缓解14例;中位疾病进展时间6.8个月（3～18.7个月）,中位生存期11.8个月.毒性反应主要是骨髓抑制和胃肠道反应,Ⅲ～Ⅳ度毒性反应发生率为60％.结论 一线接受紫杉类和卡铂化疗后复发的晚期卵巢癌患者行吉西他滨联合顺铂化疗是有效方案,毒性可耐受.

Gemcitabine plus cisplatin as second-line chemotherapy for refractory metastatic ovarian cancer

Objective To determine the efficacy and toxicity of gemcitabine plus cisplatin in carboplatin and taxane-pre- treated patients with advanced ovarian cancer. Method Chemo-resistance was defined as no response while receiving first-line chemotherapy. Patients with advanced and chemo-resistant ovarian cancer, which was confirmed histologically, received gemcit- ahine 1.0 m~m2 i. v. , dl, d8, and cisplatin 25 mg/m2 i. v. , dl - d3, with every 3 weeks being one cycle. At least, 2 cycles were delivered at least. Result Of the 30 patients, there were 3 CRs （ complete response 10. 0% ） and 13 PRs （partial response 43.3% ）. Stable disease was seen in 11 patients （36. 7% ）, and disease progression in 3 patients （ 10. 0% ）, and the overall ob- jective response was 53.3%. The median time to progression was 6. 8 months with a range of 3 to18.7 months. Median overall survival was 11.8 months. Toxieities are mainly myelosuppression and gastrointestinal reaction. Grade m -1V toxicities were de- veloped in 60% patients. There were no treatment-related deaths. Conclusion These data indicate that the colrdaination of gem- citabine and cisplatin is an effective treatment for patients with relapsed ovarian cancer with manageable toxicity.